
Its creators began trials with patients between the ages of 18 and 70 in early 2008, focusing primarily on those in whom the medication does not work. The success of the new invention would have a great impact if we consider that 1 in 200 people suffer epileptic seizures , and in 1 out of 3 cases the drugs fail to control them.
They are currently working on the development of this RNS device against this type of attack.